Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited
- P/E ratio
- 10.72
Your view on CUV.AX
Overview
What the company does, where it operates, and who runs it.
About Clinuvel Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Philippe Jacques Wolgen
- Headquarters
- 535 Bourke Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Philippe Jacques Wolgen
- Headquarters
- 535 Bourke Street, Melbourne, VIC, AU
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets.
The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP).
Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Clinuvel Pharmaceuticals Limited from FRC's valuation model, read against the market price. CUV.AX last traded at AUD 9.44, 10.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Clinuvel Pharmaceuticals Limited. Starting points for Clinuvel Pharmaceuticals Limited: P/E 10.7, EPS AUD 0.68, beta 0.61 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Clinuvel Pharmaceuticals Limited. Clinuvel Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Clinuvel Pharmaceuticals Limited. Trailing twelve-month EPS for Clinuvel Pharmaceuticals Limited stands at AUD 0.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterJun 2018 | Next quarterJun 2019 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.48 | AUD 0.47 | AUD 0.67 | AUD 0.69 |
| Lowest estimate | AUD 0.47 | AUD 0.34 | AUD 0.61 | AUD 0.52 |
| Highest estimate | AUD 0.50 | AUD 0.62 | AUD 0.80 | AUD 0.98 |
| Number of analysts | 2 | 3 | 5 | 5 |
| A year ago | — | — | AUD 0.68 | — |
| Growth vs a year ago | — | — | −1.8% | — |
Revenue estimates
| Total | This quarterJun 2018 | Next quarterJun 2019 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 46.99M | AUD 41.87M | AUD 93.17M | AUD 98.61M |
| Lowest estimate | AUD 44.91M | AUD 30.07M | AUD 88.57M | AUD 84.48M |
| Highest estimate | AUD 47.23M | AUD 52.54M | AUD 97.37M | AUD 121.71M |
| Number of analysts | 2 | 3 | 6 | 6 |
| A year ago | — | — | AUD 94.02M | — |
| Growth vs a year ago | — | — | −0.9% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Clinuvel Pharmaceuticals Limited. Clinuvel Pharmaceuticals Limited has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| BOT.AXBotanix Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| PHVSPharvaris N.V. | Healthcare | NASDAQ | $2.2B | ||
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $41.0M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $12.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $9.9M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $254.6M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $80.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $3.0M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.2M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.01% | |
| SCHCSchwab International Small-Cap Equity ETF | $5.4B in assets | 0.01% | |
| GWXState Street SPDR S&P International Small Cap ETF | $882M in assets | 0.02% | |
| ISCFiShares International Small-Cap Equity Factor ETF | $717M in assets | 0.01% | |
| AVDSAvantis International Small Cap Equity ETF | $379M in assets | 0.01% | |
| DISVDimensional - International Small Cap Value ETF | $5.1B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in CUV.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Clinuvel Pharmaceuticals Limited. Coverage tracks Clinuvel Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Clinuvel Pharmaceuticals Limited.